A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a severely debilitating disease of unknown pathogenesis consisting of a variety of symptoms including severe fatigue. The objective of the study was to examine the efficacy and safety of a TLR-3 agonist, rintatolimod (Poly I: C(12)U), in...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: David R Strayer, William A Carter, Bruce C Stouch, Staci R Stevens, Lucinda Bateman, Paul J Cimoch, Charles W Lapp, Daniel L Peterson, Chronic Fatigue Syndrome AMP-516 Study Group, William M Mitchell
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Public Library of Science (PLoS) 2012-01-01
Seri Bilgileri:PLoS ONE
Online Erişim:http://europepmc.org/articles/PMC3303772?pdf=render

Internet

http://europepmc.org/articles/PMC3303772?pdf=render

Benzer Materyaller